The treatment landscape of metastatic hormone-sensitive prostate cancer (mHSPC) has transformed significantly with the advent of triplet therapy involving androgen deprivation therapy (ADT), docetaxel, and androgen receptor signalling inhibitors (ARSIs). While clinical guidelines increasingly support early intensification, real-world practice remains challenged by patient heterogeneity, evolving evidence, and limited consensus on treatment sequencing. This narrative review integrates evidence from landmark trials, clinical guidelines, and expert insights from oncologists managing mHSPC in India. Findings affirm that triplet therapy, particularly with darolutamide, improves survival in high-volume disease and underscores the need for personalized treatment based on disease burden, comorbidities, and genomic profiles. The review also highlights gaps in real-world data, sequencing strategies, and biomarker-driven therapy, reinforcing the need for precision medicine and locally relevant evidence to guide treatment. Ultimately, optimizing mHSPC management requires harmonizing guideline-based approaches with individualized, real-world decision making to improve patient outcomes.
Sarcoma of the breast represents a rare entity accounting for <1% of all breast tumors. Liposarcoma (LPS) of the breast is an exceedingly rare malignancy with an incidence of 0.3% of all breast sarcomas and myxoid LPS (MLPS), the second most common subtype of LPS, is even rarer in breast tissue. We present a notable case of MLPS affecting the breast of a 35-year-old male patient. The patient presented with a painless swelling in the left breast, which was subsequently diagnosed with MLPS through histopathological analysis following wide local excision. The tumor exhibited low mitotic count, clear resected margins, and positivity for S-100 on immunohistochemistry. Postoperative positron emission computerized tomography revealed no residual disease, and the patient received postoperative radiation therapy to minimize the risk of local recurrence. MLPS management requires a tailored approach, considering tumor size, location, and histological characteristics. Achieving negative margins through surgical resection remains crucial, with standardized definitions aiding in treatment consistency. The present case highlights the challenges in managing rare breast sarcomas and emphasizes the importance of a multidisciplinary approach to optimize patient outcomes.
2 August 2024 in Indian Journal of Gynecologic Oncology